Hyperbaric Oxygen Therapy for Long COVID: Research Update

Long COVID, formally known as Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), has emerged as one of the most significant health challenges following the COVID-19 pandemic. Affecting a substantial number of individuals who contracted SARS-CoV-2, this condition is characterized by persistent symptoms that continue for weeks, months, or even years after the initial infection has resolved. As the medical community continues to search for effective interventions, researchers have begun investigating whether hyperbaric oxygen therapy (HBOT) may offer meaningful benefits for those living with long COVID symptoms.

This article reviews the current state of published, peer-reviewed research on HBOT and long COVID, explains the proposed mechanisms through which HBOT may address post-COVID symptoms, and provides important context about where this research stands today.

Understanding Long COVID and Post-COVID Syndrome

Long COVID describes a wide range of health problems that persist after the acute phase of a COVID-19 infection. According to the World Health Organization, post-COVID condition generally involves symptoms that last for at least two months and cannot be explained by an alternative diagnosis. The condition can affect individuals regardless of the severity of their initial infection, including those who experienced only mild acute illness.

Common long COVID symptoms include persistent fatigue, cognitive difficulties commonly described as "brain fog," sleep disturbances, chronic pain, shortness of breath, headaches, and mood changes including anxiety and depression. Some individuals also experience cardiovascular symptoms, gastrointestinal problems, and exercise intolerance. These symptoms can significantly impact daily functioning and quality of life, and for many individuals, they persist despite conventional treatments.

Researchers have proposed several mechanisms that may underlie long COVID symptoms, including persistent micro-vascular damage, chronic inflammation, mitochondrial dysfunction, and immune system dysregulation. The multi-system nature of the condition has made it particularly challenging to treat with a single intervention, which is one reason researchers have turned their attention to therapies like HBOT that may address multiple pathways simultaneously.

The Landmark 2022 Randomized Controlled Trial

One of the most significant studies in this field was published in 2022 in the journal Scientific Reports (part of the Nature Portfolio). Conducted by Zilberman-Itskovich et al. at the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Israel, this was a randomized, double-blind, sham-controlled trial, which is considered one of the most rigorous study designs in clinical research.

The study enrolled patients who had been experiencing post-COVID symptoms for at least three months following a confirmed SARS-CoV-2 infection. Participants were randomly assigned to receive either HBOT (40 sessions at 2.0 ATA with 100% oxygen) or a sham treatment designed to mimic the HBOT experience without delivering therapeutic levels of oxygen under pressure. The double-blind design meant that neither the participants nor the evaluating clinicians knew which group each patient was assigned to, reducing the risk of bias.

The results were notable. According to the published data, the HBOT group demonstrated statistically significant improvements compared to the sham group across several domains. Cognitive function, as measured by validated neuropsychological testing, showed meaningful improvement in the HBOT group. Participants also reported significant improvements in energy levels, sleep quality, and pain. Psychiatric symptom scores, including measures of anxiety and depression, also showed improvement in the treatment group relative to the control group.

Perhaps most compellingly, the study included brain MRI imaging that revealed changes in brain microstructure and perfusion in the HBOT group. These objective imaging findings correlated with the subjective symptom improvements reported by participants, lending additional weight to the clinical observations. The researchers specifically noted improvements in brain regions associated with cognitive and emotional processing.

While these results are encouraging, it is important to note that this was a single-center study with a relatively small sample size. The researchers themselves emphasized the need for larger, multi-center trials to replicate and confirm their findings before HBOT could be recommended as a standard treatment for long COVID.

How HBOT May Address Long COVID Symptoms

Researchers have proposed several mechanisms through which HBOT may help alleviate long COVID symptoms. These proposed mechanisms align with the known physiological effects of breathing oxygen under elevated pressure and the suspected pathological processes underlying long COVID.

Increased Tissue Oxygenation

One of the leading theories about long COVID involves persistent damage to small blood vessels (micro-vasculature), which may impair oxygen delivery to tissues throughout the body, including the brain. HBOT works by dramatically increasing the amount of oxygen dissolved in blood plasma. Based on Henry's Law of physics, breathing oxygen at elevated pressure causes significantly more oxygen to dissolve into the plasma, cerebrospinal fluid, and other body fluids. This dissolved oxygen can reach tissues that red blood cells may not easily access, particularly in areas where micro-vascular damage has compromised normal blood flow.

Reduced Neuroinflammation

Chronic inflammation, particularly in the brain and nervous system (neuroinflammation), is believed to play a central role in many long COVID symptoms, including cognitive difficulties, fatigue, and mood changes. Research suggests that HBOT may help modulate the inflammatory response by reducing levels of pro-inflammatory cytokines. Studies published in journals such as the Journal of Neuroinflammation have explored how pressurized oxygen environments may help downregulate inflammatory pathways in neural tissue. By potentially reducing neuroinflammation, HBOT may help address some of the neurological symptoms that are most debilitating for long COVID patients.

Improved Mitochondrial Function

Mitochondria are the energy-producing structures within cells, and mitochondrial dysfunction has been identified as a potential contributor to the persistent fatigue experienced by many long COVID patients. Research suggests that HBOT may support mitochondrial function by providing the increased oxygen supply that these organelles need to produce adenosine triphosphate (ATP), the primary energy currency of cells. By potentially improving cellular energy production, HBOT may help address the profound fatigue and reduced exercise tolerance that characterize long COVID for many individuals.

Promotion of Angiogenesis and Tissue Repair

Research has shown that HBOT may stimulate the growth of new blood vessels (angiogenesis) and promote tissue repair in areas with compromised blood supply. For long COVID patients who may have sustained micro-vascular damage during their acute infection, this regenerative potential is particularly relevant. Studies suggest that repeated HBOT sessions may trigger the release of growth factors and mobilize stem cells from bone marrow, which could contribute to the repair of damaged blood vessels and tissues. This mechanism may help explain why the improvements observed in research studies tend to emerge gradually over the course of multiple treatment sessions.

Other Published Research on HBOT and Post-COVID Recovery

Beyond the landmark 2022 randomized controlled trial, several other published studies and case reports have contributed to the growing body of evidence in this area. A 2021 case series published in the journal Undersea and Hyperbaric Medicine documented improvements in fatigue, cognitive function, and quality of life in a small group of long COVID patients treated with HBOT. While case series lack the rigor of randomized controlled trials, they provide initial clinical observations that help inform the design of larger studies.

Researchers at multiple institutions around the world have published reviews and analyses examining the theoretical basis for using HBOT to address post-COVID symptoms. A review published in Medical Gas Research (2021) examined the potential mechanisms by which HBOT could address the pathophysiology of long COVID, including its effects on inflammation, oxidative stress, and tissue repair. The authors concluded that HBOT represents a biologically plausible intervention for long COVID that warrants further clinical investigation.

Additional clinical trials examining HBOT for long COVID are currently registered on ClinicalTrials.gov and are being conducted at institutions in the United States, Europe, and Israel. These ongoing studies vary in their protocols, patient populations, and outcome measures, and their results will help clarify the role of HBOT in post-COVID care as they are published in the coming years.

The Science Behind Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy involves breathing concentrated oxygen inside a pressurized chamber. Under normal atmospheric conditions (1.0 ATA at sea level), oxygen is transported almost exclusively by hemoglobin in red blood cells. In a hyperbaric environment, the elevated pressure causes significantly more oxygen to dissolve directly into blood plasma, according to the well-established gas laws of physics. This dissolved oxygen can penetrate tissues that may not receive adequate oxygen delivery through normal circulatory mechanisms alone.

The increased oxygen availability in a hyperbaric environment triggers a cascade of physiological responses. Research has documented that HBOT can influence gene expression, modulate immune responses, promote the release of growth factors, and stimulate the mobilization of stem cells from bone marrow. These effects extend beyond the time spent in the chamber, with studies showing that the therapeutic benefits of repeated HBOT sessions can accumulate over time.

The FDA has cleared HBOT for 14 specific medical conditions, including decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, and radiation tissue injury. The long-standing safety record and established physiological effects of HBOT provide the scientific foundation upon which researchers are building their investigations into new applications, including long COVID.

Important Caveats and Considerations

OxyHealth Hyperbaric Chambers

OxyHealth is the global leader in hyperbaric chamber manufacturing, with over 19,000 chambers delivered to homes, clinics, hospitals, and sports facilities worldwide. All OxyHealth chambers are FDA-cleared Class II medical devices manufactured under ISO 13485 quality management standards and built to ASME PVHO-1 pressure vessel safety standards.

For individuals interested in home hyperbaric therapy, OxyHealth offers portable chambers including the Vitaeris 320 and the Respiro 270, both designed for safe, convenient daily use. For clinical settings that require higher pressures, the Fortius 420 and Quamvis 320 deliver clinical-grade performance with durable, medical-grade construction designed for high-volume daily use.

If you are interested in learning more about how OxyHealth chambers are being used by healthcare providers and individuals seeking to support their wellness, contact OxyHealth directly at 562-906-8888 or explore the full product lineup on the products page.

References